Glaucoma, the second leading cause of blindness in the world behind cataracts, is often referred to as “the silent thief of sight” because it can so easily go undetected.
In honor of March’s designation as Workplace Eye Wellness Month, the American Academy of Ophthalmology is sharing tips on how to create a comfortable work environment at home to avoid digital eye strain.
Blue light-blocking glasses, with digital device usage on the rise during the COVID-19 pandemic (particularly among children and adolescents), continue to grow in popularity.
The Glaucoma Foundation (TGF) and Research to Prevent Blindness (RPB) have partnered to launch a new grant aimed at supporting under-represented racial and ethnic minority researchers in the pursuit of glaucoma research. The TGF (sponsored by Patricia Hill) / RPB Fellowships in Glaucoma provide one-year, $10,000 fellowships focused on substantive glaucoma research.
Being able to make blind people see again sounds like the stuff of miracles or even science fiction. And it has always been one of the biggest challenges for scientists.
A meta-analysis finds that vision impairment and blindness are tied to an increased risk of mortality, prompting the need to address global eye health disparities.
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every other Wednesday.
Glaucoma Research Foundation (GRF) today announced a total of $1.7 million in annual research grants to support 13 investigators at prestigious colleges and universities across the United States.
In the largest genome-wide association study of glaucoma to date, an international team of researchers compared the genes of 34,179 people with the disease to 349,321 control subjects. They identified 127 genes linked to glaucoma, including 44 new gene loci and confirmed 83 previously reported loci.
Four brief, illuminating talks by experts on gene therapy, optic nerve regeneration, the role of artificial intelligence, and the importance of trust between physician and patient.
Coming off a successful inaugural year, Eyecelerator this week announced its slate of virtual and in-person programming scheduled for 2021, beginning with a complimentary live stream on Wednesday, March 3, 8 to 9:30 a.m. PST: Financing in the Time of COVID.
Researchers using MRI have found significant abnormalities in the eyes of some people with severe COVID-19, according to a study published in the journal Radiology.
Researchers at the University of Illinois Chicago have been awarded a five-year, $10.15 million grant to develop a broad-spectrum immunomodulatory eye drop.
Patients with age-related macular degeneration (AMD) who become infected with SARS-CoV-2, the virus that causes COVID-19, are at higher risk of developing severe complications including requiring supplemental oxygen and death.
A University of Utah Health ophthalmologist is investigating how lipids known as VLC-PUFAs could be used to prevent eye disease thanks to a new way to synthesize them for research.
For his research project studying neuroprotection in glaucoma, Pete Williams, PhD from the Karolinska Institutet in Stockholm was awarded the 2021 Shaffer Prize for Innovative Glaucoma Research.
The AAVCOVID vaccine program, a novel gene-based vaccine strategy that utilizes an adeno-associated virus (AAV) vector, was granted an award for up to $2.1 million from the Bill & Melinda Gates Foundation. In data released in preprint, two AAVCOVID vaccine candidates led to robust neutralizing antibody responses in mouse and nonhuman primate models from only a single dose. The candidates were also shown to be safe and well-tolerated in both models.
Scientists at the National Eye Institute (NEI) have developed a promising gene therapy strategy for a rare disease that causes severe vision loss in childhood. A form of Leber congenital amaurosis, the disease is caused by autosomal-dominant mutations in the CRX gene, which are challenging to treat with gene therapy.
New research demonstrates that hypnosis—the process of focusing a person’s attention on a specific task or sensation—can turn a normally difficult visual task into a far easier one by helping individuals mentally “fill in the gaps” of missing visual cues.
Less than twenty years ago, most people diagnosed with advanced age-related macular degeneration (AMD) were destined to become legally blind. Today, advances in the diagnosis and treatment of AMD made possible by retina specialists allow many patients with advanced AMD to keep reading, driving and enjoying their independence.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipient of the Pfizer Ophthalmics Carl Camras Translational Research Award. The award, funded by Pfizer Ophthalmics through the ARVO Foundation, honors Dr. Carl Camras, who is highly respected for his work as a glaucoma specialist and a research scientist, by annually awarding up to three $12,000 awards to young investigators working in areas of translational research. The 2021 awardee is Alex Huang, MD, PhD of the Doheny Eye Institute and University of California in Los Angeles.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipient of the Mallinckrodt Uveitis Research Fellowship, generously funded by Mallinckrodt Pharmaceuticals. The award, funded through the ARVO Foundation, supports an early career investigator with a one-year grant of $45,000 to study an aspect of uveitis or other inflammatory conditions of the eye. The 2021 awardee is Shilpa Kodati, MD of the National Eye Institute (NEI) at the National Institutes of Health (NIH).
Dr. Mary Beth Cunnane, a radiologist who specializes in the imaging of patients with diseases of the eyes, ears, nose and head and neck, has been appointed Chief of Radiology at Mass Eye and Ear in Boston.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the 2021 recipients of the Dr. David L. Epstein Award. Jamie Craig, MBBS, FRANZCO, DPhil and Owen Siggs, MD, DPhil, are the recipients of the $100,000 award which is funded through the ARVO Foundation.
The latest episode of “On Tech and Vision with Dr. Cal Roberts” centers on the place where big ideas are born – the human brain. The host, Calvin W. Roberts, MD, President and CEO of Lighthouse Guild, explores theories of brain plasticity, sensory substitution, and sensory augmentation with his guests Dr. Patricia Grant, Director of Clinical Research at Wicab Inc., and Dr. John-Ross Rizzo, Director of Innovation and Technology and Assistant Professor in the Department of Rehabilitation Medicine and the Department of Neurology, NYU Langone Medical Center.
The Catalyst Award will be presented to Ramin Valian of Allergan, an AbbVie Company, in recognition of Allergan's ongoing leadership and commitment to the development of innovative treatments to advance glaucoma care.
Retinal cells derived from a cadaver human eye survived when transplanted into the eyes of primate models, an important advance in the development of cell therapy to treat blindness, according to a study published on January 14 in Stem Cell Reports.
In experiments in mouse tissues and human cells, Johns Hopkins Medicine researchers say they have found that removing a membrane that lines the back of the eye may improve the success rate for regrowing nerve cells damaged by blinding diseases. The findings are specifically aimed at discovering new ways to reverse vision loss caused by glaucoma and other diseases that affect the optic nerve, the information highway from the eye to the brain.
What if the degenerative eye conditions that lead to glaucoma, corneal dystrophy, and cataracts could be detected and treated before vision is impaired? Recent findings from the lab of Investigator Ting Xie, PhD, at the Stowers Institute for Medical Research point to the ciliary body as a key to unlocking this possibility.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the 2021 recipients of the Roche Collaborative Research Fellowships. Wanjiku Mathenge MBChB, MMed, MSc, PhD, Sudhir H Ranganath, PhD, and Pablo Federico Barcelona, PhD, are the recipients of the fellowships that are generously funded by F. Hoffmann-La Roche Ltd., through the ARVO Foundation.
The Association for Research in Vision and Ophthalmology (ARVO) today announced the recipients of the Lewis Rudin Glaucoma Prize. The award, funded by the May and Samuel Rudin Family Foundation with support of his brother Jack Rudin via the ARVO Foundation, provides a $30,000 award in recognition of an outstanding scholarly article on glaucoma published in a peer-reviewed journal during the previous calendar year. The 2020 recipients are Iqbal Ahmad Ph.D. and Pooja Teotia, PhD, of the University of Nebraska in Omaha, Neb.
The Association for Research in Vision and Ophthalmology (ARVO) announced today the recipients of the 2021 Genentech Age-Related Macular Degeneration (AMD) Research Fellowships. The two recipients will each receive $40,000 to support research focused on an aspect of AMD. The 2021 recipients are Yi-Rong Peng, PhD and Kevin J. McHugh, PhD.
Eye care is a complex field that involves several unique specialists. Optometrists, ophthalmologists, pediatric ophthalmologists, orthoptists and opticians are specially trained to handle different aspects of your eye care.
Diabetes continues to be the leading cause of new cases of blindness among adults in the United States. But the current shortage of eye-care providers would make it impossible to keep up with demand to provide the requisite annual screenings for this population. A new study looks at the effectiveness of seven artificial intelligence-based screening algorithms to diagnose diabetic retinopathy, the most common diabetic eye disease leading to vision loss.
The Association for Research in Vision and Ophthalmology (ARVO) today announced Yohei Tomita, MD, PhD, has received the 2021 Bert M. Glaser, MD Award for Innovative Research in Retina, which recognizes an early-career investigator who has made a novel discovery that impacted the understanding and/or treatment of a retinal disease or condition. Tomita is recognized with this award for his retinal translational research, with a focus on diabetic retinopathy (DR) and age-related macular degeneration (AMD).
In older people with type 1 diabetes, damage to the retina may be linked to memory problems and other cognitive conditions.BOSTON – (December 31, 2020) – As they age, people with diabetes are more likely to develop Alzheimer's disease and other cognitive disorders than are people without diabetes. Scientists at Joslin Diabetes Center now have shown that routine eye imaging can identify changes in the retina that may be associated with cognitive disorders in older people with type 1 diabetes.
The COVID-19 pandemic has presented many challenges including delayed eye doctor appointments. This video will discuss changes eye doctors have made to improve safety during every step of the office visit.
The Regulatory Relief Coalition (RRC), a group of national physician specialty organizations, announced its strong support for the Improving Seniors' Timely Access to Care Act, legislation introduced today in the U.S. Senate by Senators Sherrod Brown (D-OH) and John Thune (R-SD).
Researchers at the University of Illinois Chicago have published a study showing a promising approach to using drug repurposing to treat genetic diseases. A team from the UIC Department of Ophthalmology and Visual Sciences published the article, “Gene dosage manipulation alleviates manifestations of hereditary PAX6 haploinsufficiency in mice” in the journal Science Translational Medicine.
Researchers at the National Eye Institute (NEI) report that a brain region in the superior temporal sulcus (fSTS) is crucial for processing and making decisions about visual information.